Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Excipients without active substance - Lyophilised powder for solution for injection - Intramuscolar Use
Ipsen
Treatment of moderate to severe glabellar lines
1 trial -
Experimental vaccine
Sinovac Research and Development Co.,
Poliomyelitis
1 trial -
Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
Kunming Hope of Health Hospital
Elderly AML Patients
1 trial -
Extended Release Buprenorphine
BRIGHT MINDS BIOSCIENCES INC.
Substance Use Disorder
1 trial -
Extended Release Naltrexone
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use Disorder
1 trial -
Extended treatment
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
Extended-release Guanfacine HCl (Intuniv, SPD503)
Takeda
Attention Deficit Hyperactivity Disorder (ADHD)
1 trial -
Extended-release Guanfacine Hydrochloride
Takeda
Attention-deficit/Hyperactivity Disorder
3 trials -
Eylea 40 mg/mL solution for injection in a vial
Lacuna Pharma Pty Ltd
Retinopathy of prematurity (ROP)
1 trial -
FAT EMULSIONS , Triheptanoin
Lacuna Pharma Pty Ltd
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
1 trial -
FE 999913 vaginal tablet
Ferring Pharmaceuticals
Luteal Hormone Supplementation
1 trial -
FF/GW642444 Inhalation Powder
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
2 trials -
FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -
AstraZeneca AB
Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.
1 trial -
FKB238 (bevacizumab)
Centus Biotherapeutics Europe Limited
Carcinoma, Non-Small-Cell Lung
1 trial -
FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%
The George Institute
Patients with hip or knee infections
1 trial -
FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA
Fondazione Telethon ETS
Higher-risk-myelodysplastic syndromes
1 trial -
FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE
Arcus Biosciences
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer
1 trial -
FLUOROURACIL, CISPLATIN, CAPECITABINE, CISPLATIN, TRASTUZUMAB, Placebo for Pembrolizumab, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, TRASTUZUMAB
Merck Sharp and Dohme
Gastric or gastroesophageal junction (GEJ) adenocarcinoma
1 trial -
FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE
Verona Pharma Ireland Limited
Gastric adenocarcinoma with peritoneal metastases
1 trial -
FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN
The George Institute
stage III colon adenocarcinoma with deficient MMR
1 trial -
FST-201 (dexamethasone 0.1%) Otic Suspension
Takeda
Acute Fungal Otitis Externa
1 trial -
FST-201 (dexamethasone 0.1%) Otic Suspension
Takeda
Acute Otitis Externa
1 trial -
FST201 (dexamethasone 0.1% with povidone-iodine 1%)
Takeda
Acute Otitis Externa
1 trial -
Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.
Sanofi-aventis Healthcare Pty Ltd
Fabryβs disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources